{
  "@context": "https://schema.org",
  "@type": "Dataset",
  "name": "India semaglutide brand/price/legitimacy dataset",
  "description": "Brand-level tracker of India's generic semaglutide market following the March 2026 patent expiry: manufacturer, formulation, monthly and per-shot price bands in INR, DCGI status, and a per-row source-verification level. Compiled from public sources only; every row carries its source URLs.",
  "version": "2026-08-25.v3",
  "dateModified": "2026-08-25",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "creator": {
    "@type": "Organization",
    "name": "Magistra",
    "url": "https://magistra.health"
  },
  "isBasedOn": "https://magistra.health/en/methodology",
  "distribution": [
    {
      "@type": "DataDownload",
      "encodingFormat": "text/csv",
      "contentUrl": "https://magistra.health/data/india-semaglutide-tracker.csv"
    }
  ],
  "disclaimer": "Educational and informational data only. Magistra does not sell, prescribe, promote, or deliver any medication, and does not recommend any brand. Prices are as reported by the cited sources on the stated date and change frequently. Data, not investment advice.",
  "context": {
    "patentExpiry": "Novo Nordisk's core Indian semaglutide patent expired 2026-03-20; first generic launches 2026-03-21; >15 generics within two days, >40 brands by end of April 2026",
    "priceDropVsInnovator": "70–90%",
    "marketSize": "Indian GLP-1 agonist market ~Rs 1,446 crore (Goodreturns, 2026-03); projected $1bn semaglutide market in India over two years (Pearce IP)",
    "marketShare": {
      "asOf": "2026-03",
      "semaglutideShareOfIndiaGLP1Market": "33% in March 2026, up from 25% in February — ALL semaglutide brands combined (branded Ozempic/Wegovy + generics), NOT generics alone",
      "tirzepatideShareOfIndiaGLP1Market": "Mounjaro (Eli Lilly) fell from 71% to 64% over the same February→March window",
      "withinSemaglutide": "Novo Nordisk holds ~70% of the semaglutide slice; Torrent Pharmaceuticals ~8% (largest generic)",
      "volumeNote": "40+ drugmakers launched generic semaglutide; volume more than doubled month-over-month in March 2026",
      "basis": "value-vs-volume basis not stated in the cited source; treat as reported share, unit unspecified",
      "source": "eMarketer 2026-04-09 (citing Bloomberg), verified by direct fetch of the article 2026-08-25; the article's own headline ('generic semaglutide climbs to 33%') conflicts with its body text — the body text is what this entry records. Its 'generics launched in January' claim also conflicts with the multi-source 2026-03-20/21 launch dates in context.patentExpiry and is not adopted.",
      "sourceKeys": [
        "emarketer_share"
      ]
    }
  },
  "verificationLevels": {
    "multi": "fact appears in ≥2 independent sources",
    "single": "fact appears in exactly 1 source — treat as unconfirmed until corroborated (on-ground validation or second source)",
    "null": "not found in any source consulted — unknown, NOT zero"
  },
  "knownGaps": [
    "Strength-level pricing (₹ per mg-tier) missing for most brands — needed for a true like-for-like comparison",
    "DCGI approval status unconfirmed for ~10 of 25 rows — CDSCO public databases are the primary source to check next",
    "RESOLVED v2: oral generic exists — Torrent Semalix, DCGI-approved 3/7/14 mg (India's first generic oral semaglutide). Its PRICE is still unknown; other oral generics may have followed — sweep needed",
    "Claimed >40 brands by end April 2026; this file has 20 generic rows — the remaining brands need a sweep of CDSCO approvals + manufacturer press releases (candidates seen but unrowed: Cipla, Biocon, Hetero, Emcure own-generic, Aurobindo)",
    "Zero legitimacy signal beyond DCGI status: no batch-alert, recall, or substandard/counterfeit reports compiled yet (CDSCO monthly NSQ lists are the source)",
    "All prices are launch-window (March 2026) or glp1check-current — need a dated re-check; Novo cut prices post-launch and generics likely moved too",
    "PRICE-RANGE CORRECTION (v2): the widely-cited ₹220 floor is per SHOT (Eris SUNDAE vial), not per month. Monthly entry floor ₹1,290 (Eris/Natco vials); pen devices ₹1,800–4,500. Strategy-frame texts citing '₹220–4,200/mo' should read '₹1,290–4,500/mo (₹220/shot vial floor)'"
  ],
  "stats": {
    "brandsTracked": 25,
    "genericBrands": 20,
    "manufacturers": 15,
    "genericMonthlyMinINR": 1290,
    "genericMonthlyMaxINR": 8000,
    "genericMonthlySpreadMultiple": 6.2,
    "genericBrandsWithMonthlyPrice": 18,
    "innovatorMonthlyMinINR": 3999,
    "innovatorMonthlyMaxINR": 16400,
    "perShotMinINR": 220,
    "multiSourceRows": 21,
    "singleSourceRows": 4,
    "dcgiStatusKnown": 13,
    "oralFormulations": 2
  },
  "brands": [
    {
      "brand": "Obeda",
      "manufacturer": "Dr Reddy's Laboratories",
      "type": "generic",
      "formulation": "injection, pre-filled disposable pen",
      "strengths": "2 mg; 4 mg",
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": 4200,
      "priceINRPerMonthHigh": 4200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": "approved — first DCGI-approved generic semaglutide injection in India",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Usema",
      "manufacturer": "USV (co-marketing with Dr Reddy's)",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 4200,
      "priceINRPerMonthHigh": 4200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "single",
      "sources": "https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semaglyn",
      "manufacturer": "Zydus Lifesciences",
      "type": "generic",
      "formulation": "injection, reusable multi-dose pen",
      "strengths": null,
      "indications": "type 2 diabetes; obesity",
      "priceINRPerMonthLow": 2200,
      "priceINRPerMonthHigh": 5500,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "₹2,200 average per Pearce IP/Goodreturns; ₹2,200–5,500 range per glp1check",
      "dcgiStatus": "approved (T2DM and obesity)",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Mashema",
      "manufacturer": "Zydus Lifesciences",
      "type": "generic",
      "formulation": "injection, reusable multi-dose pen",
      "strengths": null,
      "indications": "type 2 diabetes; obesity",
      "priceINRPerMonthLow": 2200,
      "priceINRPerMonthHigh": 2200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": "approved (T2DM and obesity)",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Alterme",
      "manufacturer": "Zydus Lifesciences",
      "type": "generic",
      "formulation": "injection, reusable multi-dose pen",
      "strengths": null,
      "indications": "type 2 diabetes; obesity",
      "priceINRPerMonthLow": 2200,
      "priceINRPerMonthHigh": 2200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": "approved (T2DM and obesity)",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semanext",
      "manufacturer": "Lupin (semi-exclusive co-marketing of Zydus product)",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 2200,
      "priceINRPerMonthHigh": 2200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Livarise",
      "manufacturer": "Lupin (semi-exclusive co-marketing of Zydus product)",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 2200,
      "priceINRPerMonthHigh": 2200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semasize",
      "manufacturer": "Alkem Laboratories",
      "type": "generic",
      "formulation": "injection, pre-filled disposable and reusable pen options",
      "strengths": null,
      "indications": "type 2 diabetes; chronic weight management",
      "priceINRPerMonthLow": 1800,
      "priceINRPerMonthHigh": 3500,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "₹1,800/mo entry per Pearce IP; ₹1,800–3,500 range per glp1check",
      "dcgiStatus": "approved — based on Phase 3 India trials",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Obesema",
      "manufacturer": "Alkem Laboratories",
      "type": "generic",
      "formulation": "injection, pre-filled disposable and reusable pen options",
      "strengths": null,
      "indications": "type 2 diabetes; chronic weight management",
      "priceINRPerMonthLow": 1800,
      "priceINRPerMonthHigh": 1800,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": "approved — based on Phase 3 India trials",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Hepaglide",
      "manufacturer": "Alkem Laboratories",
      "type": "generic",
      "formulation": "injection, pre-filled disposable and reusable pen options",
      "strengths": null,
      "indications": "type 2 diabetes; chronic weight management",
      "priceINRPerMonthLow": 1800,
      "priceINRPerMonthHigh": 1800,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": "approved — based on Phase 3 India trials",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Noveltreat",
      "manufacturer": "Sun Pharma",
      "type": "generic",
      "formulation": "injection, pre-filled pen",
      "strengths": "5 dose strengths (per Goodreturns)",
      "indications": "weight management",
      "priceINRPerMonthLow": 3600,
      "priceINRPerMonthHigh": 8000,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Sematrinity",
      "manufacturer": "Sun Pharma",
      "type": "generic",
      "formulation": "injection, multi-dose pen",
      "strengths": null,
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": 3000,
      "priceINRPerMonthHigh": 5200,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.goodreturns.in/news/semaglutide-prices-drop-in-india-after-generic-launches-by-sun-pharma-zydus-dr-reddy-s-natco-che-1497625.html | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "GLIPIQ",
      "manufacturer": "Glenmark Pharmaceuticals",
      "type": "generic",
      "formulation": "injection, vial and pre-filled pen",
      "strengths": null,
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": 1300,
      "priceINRPerMonthHigh": 1760,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "vial format starts ~₹325/week for 0.25 mg starting dose",
      "dcgiStatus": "approved",
      "verification": "multi",
      "sources": "https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semanat",
      "manufacturer": "Natco Pharma",
      "type": "generic",
      "formulation": "injection, multi-dose vial",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 1290,
      "priceINRPerMonthHigh": 1750,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "FiercePharma quotes Natco vials at Rs 1,290–1,750/month; brand→vial mapping per generichope (single source for the mapping)",
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.fiercepharma.com/pharma/novos-semaglutide-losing-patent-protection-indian-drugmakers-set-launch-their-generics | https://www.multibagg.ai/market-pulse/articles/semaglutide-generics-india-patent-expiry-cmmx2u78c5syts30js14a63zi | https://www.glp1check.in/semaglutide-brands-india | https://generichope.com/semaglutide-price-india-generic-brands-comparison/"
    },
    {
      "brand": "Semafull",
      "manufacturer": "Natco Pharma",
      "type": "generic",
      "formulation": "injection, pen device",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 4000,
      "priceINRPerMonthHigh": 4500,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "FiercePharma quotes Natco pen devices at Rs 4,000–4,500/month; brand→pen mapping per generichope (single source for the mapping)",
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.fiercepharma.com/pharma/novos-semaglutide-losing-patent-protection-indian-drugmakers-set-launch-their-generics | https://www.glp1check.in/semaglutide-brands-india | https://generichope.com/semaglutide-price-india-generic-brands-comparison/"
    },
    {
      "brand": "SUNDAE",
      "manufacturer": "Eris Lifesciences (with Natco Pharma)",
      "type": "generic",
      "formulation": "injection, multi-dose vial (2 mg/1.5 ml and 4 mg/3 ml); pen device added April 2026",
      "strengths": "2 mg/1.5 ml; 4 mg/3 ml",
      "indications": "type 2 diabetes; obesity",
      "priceINRPerMonthLow": 1290,
      "priceINRPerMonthHigh": 4500,
      "priceINRPerShot": 220,
      "priceAsOf": "2026-08",
      "priceNote": "₹220/shot = lowest semaglutide entry price globally; vial from ₹1,290/month; April pen version at ₹4,000/₹4,200/₹4,500 per month",
      "dcgiStatus": "approved February 2026 (T2D and obesity)",
      "verification": "multi",
      "sources": "https://www.findoc.com/news/market-news/7/15/1230810 | https://www.outlookbusiness.com/corporate/eris-natco-announce-launch-of-generic-semaglutide-brands-as-patent-expires | https://clival.com/news/eris-lifesciences-disrupts-the-glp-1-market-with-220-semaglutide-shot | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Sembolic",
      "manufacturer": "Torrent Pharmaceuticals (injectable co-marketed with Zydus Lifesciences)",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": "type 2 diabetes; obesity",
      "priceINRPerMonthLow": 3999,
      "priceINRPerMonthHigh": 3999,
      "priceINRPerShot": null,
      "priceAsOf": "2026-03",
      "priceNote": "injectable starting price Rs 3,999/month",
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.torrentpharma.com/docs/Press_Release_a634006544.pdf | https://www.angelone.in/news/stocks/torrent-pharma-expands-diabetes-and-obesity-portfolio-with-sembolic-and-semalix | https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/885428/torrent-pharma-enters-glp-1-space-with-first-generic-oral-semaglutide-in-india/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semalix",
      "manufacturer": "Torrent Pharmaceuticals",
      "type": "generic",
      "formulation": "oral, daily tablet — India's FIRST generic oral semaglutide",
      "strengths": "3 mg; 7 mg; 14 mg",
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": null,
      "priceINRPerMonthHigh": null,
      "priceINRPerShot": null,
      "priceAsOf": null,
      "priceNote": null,
      "dcgiStatus": "approved (oral, 3/7/14 mg strengths)",
      "verification": "multi",
      "sources": "https://www.torrentpharma.com/docs/Press_Release_a634006544.pdf | https://www.angelone.in/news/stocks/torrent-pharma-expands-diabetes-and-obesity-portfolio-with-sembolic-and-semalix | https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/885428/torrent-pharma-enters-glp-1-space-with-first-generic-oral-semaglutide-in-india/ | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Semabest",
      "manufacturer": "MSN Laboratories",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": 3990,
      "priceINRPerMonthHigh": 3990,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "single",
      "sources": "https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Samakind",
      "manufacturer": "Mankind Pharma",
      "type": "generic",
      "formulation": "injection",
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": null,
      "priceINRPerMonthHigh": null,
      "priceINRPerShot": null,
      "priceAsOf": null,
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "multi",
      "sources": "https://www.businesstoday.in/industry/pharma/story/sun-pharma-dr-reddys-zydus-mankind-among-first-movers-as-indias-semaglutide-market-opens-post-patent-expiry-521337-2026-03-19 | https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Ozempic",
      "manufacturer": "Novo Nordisk",
      "type": "innovator",
      "formulation": "injection, weekly pen",
      "strengths": null,
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": 5660,
      "priceINRPerMonthHigh": 9100,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": "Novo cut prices further as generics entered (BusinessToday 2026-03-31)",
      "dcgiStatus": "approved (innovator)",
      "verification": "multi",
      "sources": "https://www.glp1check.in/semaglutide-brands-india | https://www.businesstoday.in/industry/pharma/story/novo-further-cuts-semaglutide-prices-as-generics-enter-india-523336-2026-03-31"
    },
    {
      "brand": "Wegovy",
      "manufacturer": "Novo Nordisk",
      "type": "innovator",
      "formulation": "injection, weekly pen",
      "strengths": null,
      "indications": "chronic weight management",
      "priceINRPerMonthLow": 3999,
      "priceINRPerMonthHigh": 16400,
      "priceINRPerShot": null,
      "priceAsOf": "2026-08",
      "priceNote": null,
      "dcgiStatus": "approved (innovator)",
      "verification": "multi",
      "sources": "https://www.glp1check.in/semaglutide-brands-india | https://www.businesstoday.in/industry/pharma/story/novo-further-cuts-semaglutide-prices-as-generics-enter-india-523336-2026-03-31"
    },
    {
      "brand": "Rybelsus",
      "manufacturer": "Novo Nordisk",
      "type": "innovator",
      "formulation": "oral, daily tablet",
      "strengths": null,
      "indications": "type 2 diabetes",
      "priceINRPerMonthLow": null,
      "priceINRPerMonthHigh": null,
      "priceINRPerShot": null,
      "priceAsOf": null,
      "priceNote": null,
      "dcgiStatus": "approved (innovator)",
      "verification": "multi",
      "sources": "https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Extensior",
      "manufacturer": "Abbott (co-marketing Novo semaglutide)",
      "type": "innovator-comarketed",
      "formulation": null,
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": null,
      "priceINRPerMonthHigh": null,
      "priceINRPerShot": null,
      "priceAsOf": null,
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "single",
      "sources": "https://www.glp1check.in/semaglutide-brands-india"
    },
    {
      "brand": "Poviztra",
      "manufacturer": "Emcure (co-marketing Novo semaglutide)",
      "type": "innovator-comarketed",
      "formulation": null,
      "strengths": null,
      "indications": null,
      "priceINRPerMonthLow": null,
      "priceINRPerMonthHigh": null,
      "priceINRPerShot": null,
      "priceAsOf": null,
      "priceNote": null,
      "dcgiStatus": null,
      "verification": "single",
      "sources": "https://www.glp1check.in/semaglutide-brands-india"
    }
  ]
}